tradingkey.logo

U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent

ReutersDec 30, 2024 11:40 AM

- Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arcutis Biotherapeutics, Artiva Biotherapeutics and Nuvalent on Monday.

HIGHLIGHTS

Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating

Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating

Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110

Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order

Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating

Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating

BigBear.ai Holdings Inc BBAI.N: H.C. Wainwright raises PT to $7 from $3

Boston Scientific Corp BSX.N: BTIG raises target price to $101 from $97

Emergent Biosolutions EBS.N: H.C. Wainwright initiates coverage with buy rating; PT $15

Exelixis Inc EXEL.O: RBC raises target price to $38 from $34

Insulet Corp PODD.O: BTIG raises target price to $300 from $270

Metavia Inc MTVA.O: H.C. Wainwright initiates coverage with buy rating; PT $12

Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI